Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, et al.
The Lancet (2021) Vol. 398, Iss. 10308, pp. 1344-1357
Closed Access | Times Cited: 1090

Showing 1-25 of 1090 citing articles:

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Patrick M. Forde, Jonathan Spicer, Shun Lü, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 21, pp. 1973-1985
Open Access | Times Cited: 1680
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 6, pp. 491-503
Closed Access | Times Cited: 552
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Mary O’Brien, Luis Paz‐Ares, Sandrine Marréaud, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 10, pp. 1274-1286
Closed Access | Times Cited: 461
Immune checkpoint therapy—current perspectives and future directions
Padmanee Sharma, Sangeeta Goswami, Deblina Raychaudhuri, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1652-1669
Closed Access | Times Cited: 449
Non‐small cell lung cancer in China
Peixin Chen, Yunhuan Liu, Yaokai Wen, et al.
Cancer Communications (2022) Vol. 42, Iss. 10, pp. 937-970
Open Access | Times Cited: 365
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
Masahiro Tsuboi, Roy S. Herbst, Thomas John, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 2, pp. 137-147
Closed Access | Times Cited: 332
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Meng‐Ling Wu, Qianrui Huang, Yao Xie, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 296
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
John V. Heymach, David H. Harpole, Tetsuya Mitsudomi, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 18, pp. 1672-1684
Open Access | Times Cited: 276
Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy
Jordi Remón, Jean‐Charles Soria, Solange Peters
Annals of Oncology (2021) Vol. 32, Iss. 12, pp. 1637-1642
Open Access | Times Cited: 272
Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
Mariano Provencio, Ernest Nadal, J.L. González-Larriba, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 6, pp. 504-513
Open Access | Times Cited: 261
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
Melissa L. Johnson, Byoung Chul Cho, Alexander Luft, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 6, pp. 1213-1227
Open Access | Times Cited: 252
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
Roy S. Herbst, Yi‐Long Wu, Thomas John, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 10, pp. 1830-1840
Open Access | Times Cited: 229
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
Hirva Mamdani, Sandro Matosevic, Ahmed Bilal Khalid, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 223
Single-cell spatial landscapes of the lung tumour immune microenvironment
Mark Sorin, Morteza Rezanejad, Elham Karimi, et al.
Nature (2023) Vol. 614, Iss. 7948, pp. 548-554
Open Access | Times Cited: 207
Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
Hamid Mithoowani, Michela Febbraro
Current Oncology (2022) Vol. 29, Iss. 3, pp. 1828-1839
Open Access | Times Cited: 176
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer
Jia‐Tao Zhang, Si‐Yang Liu, Wei Gao, et al.
Cancer Discovery (2022) Vol. 12, Iss. 7, pp. 1690-1701
Open Access | Times Cited: 151
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
Shun Lü, Wei Zhang, Lin Wu, et al.
JAMA (2024) Vol. 331, Iss. 3, pp. 201-201
Open Access | Times Cited: 138
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
Yi‐Long Wu, Rafał Dziadziuszko, Jin Seok Ahn, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 14, pp. 1265-1276
Closed Access | Times Cited: 133
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
Tina Cascone, Cheuk Hong Leung, Annikka Weissferdt, et al.
Nature Medicine (2023) Vol. 29, Iss. 3, pp. 593-604
Open Access | Times Cited: 130
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial
Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, et al.
Annals of Oncology (2023) Vol. 34, Iss. 10, pp. 907-919
Open Access | Times Cited: 129
Perioperative Nivolumab in Resectable Lung Cancer
Tina Cascone, Mark M. Awad, Jonathan Spicer, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 19, pp. 1756-1769
Closed Access | Times Cited: 125
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial
Joe Y. Chang, Steven H. Lin, Wenli Dong, et al.
The Lancet (2023) Vol. 402, Iss. 10405, pp. 871-881
Open Access | Times Cited: 121
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, et al.
JAMA Oncology (2023) Vol. 9, Iss. 4, pp. 527-527
Open Access | Times Cited: 120
Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment
Nicole Kirchhammer, Marcel P. Trefny, Priska Auf der Maur, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 670
Closed Access | Times Cited: 117
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study
Alessandro Rizzo, Veronica Mollica, Valentina Tateo, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 6, pp. 1381-1394
Closed Access | Times Cited: 112
Page 1 - Next Page

Scroll to top